Vise Technologies’s Novavax NVAX Stock Holding History

Vise Technologies’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,103	Closed	-$69.9K	–	1220
2025 Q2	$69.9K	Buy	+11,103	New	+$73.5K	﹤0.01%	1044

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vise Technologies's NVAX Position: Q3 2025 in Review

Vise Technologies sold out of Novavax (NVAX) in Q3 2025, closing a stake of 11,103 shares — an estimated $69.9K sold.

Vise Technologies first reported a position in NVAX in Q2 2025 and held it in 1 quarter. The position peaked at $69.9K in Q2 2025. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

Vise Technologies reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
Vise Technologies sold 11,103 Novavax shares in Q3 2025, an estimated $69.9K.
Vise Technologies first reported a position in Novavax in Q2 2025 and held it in 1 quarter.
Vise Technologies's Novavax position peaked at $69.9K in Q2 2025.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Vise Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.